{
  "extraction_metadata": {
    "timestamp": "2025-10-02T13:51:52.936814",
    "source_type": "clinical_guideline",
    "indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
    "total_countries": 11,
    "temperature": 0.01
  },
  "outcomes_by_country": {
    "AT": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "AT",
      "Outcomes": "overall survival, progression-free survival, partial response, complete remission, time to progression of the tumor, time to deterioration, intraoperative complications, mortality, morbidity, disease progression, adverse events, neurotoxicity, EORTC QLQ-C30, EQ-5D-5L, imaging response (RECIST criteria), imaging response (mRECIST criteria)",
      "ChunksUsed": 12,
      "ContextTokens": 2893
    },
    "BE": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "BE",
      "Outcomes": "partial response, survival, objective response, liver failure, pain, fever, serious complications, portal vein thrombosis, recurrence, delay of recurrence, adverse events (general), quality of life",
      "ChunksUsed": 12,
      "ContextTokens": 2963
    },
    "DE": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "DE",
      "Outcomes": "overall survival, progression-free survival, partial response, complete remission, response rates (mRECIST), intraoperative complications, mortality, morbidity, disease progression, time to deterioration, time to progression of the tumor, adverse events, neurotoxicity, EORTC QLQ-C30, EQ-5D-5L, Social Code Standardized incidence rate",
      "ChunksUsed": 12,
      "ContextTokens": 2893
    },
    "DK": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "DK",
      "Outcomes": "long-term survival, perioperative mortality, morbidity, leukaemia, postoperative softening, gallbladder abscess, recurrence, quality of life",
      "ChunksUsed": 12,
      "ContextTokens": 2057
    },
    "ES": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "ES",
      "Outcomes": "survival, prognosis (BCLC staging system), adverse events, long-term treatment-related complications",
      "ChunksUsed": 12,
      "ContextTokens": 2639
    },
    "EU": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "EU",
      "Outcomes": "bleeding, tumour seeding, side-effects (biopsy), diagnosis (multiphasic CT and MRI, LI-RADS v2018), diagnosis (immunohistochemistry markers), diagnosis (panels of immunohistochemistry markers), diagnosis (genetic tests for metabolic diseases), diagnosis (paired tumour and non-tumour liver biopsy), diagnosis (non-invasive imaging-based criteria on CT, MRI, or CEUS), diagnosis (specialised molecular and genetic tests), diagnosis (pathological examination), diagnosis (differential diagnosis between HCC and other liver tumours), diagnosis (differential diagnosis between HCC and benign nodules)",
      "ChunksUsed": 11,
      "ContextTokens": 2774
    },
    "FR": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "FR",
      "Outcomes": "time-to-progression, toxicity, overall survival, response rates (RECIST criteria), adverse events, diarrhoea, fatigue, nausea, neutropenia, EORTC QLQ-C30, EORTC QLQ-LC13, EQ-5D-5L",
      "ChunksUsed": 12,
      "ContextTokens": 3575
    },
    "IT": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "IT",
      "Outcomes": "improved survival, response rates, adverse events, safety, efficacy, rebleeding, liver-related morbidity, mortality, prognosis (Child-Pugh score), prognosis (MELD score), cost-effectiveness, false positives, hypersensitivity to monitoring, tolerance of treatment, down-staging, donor morbidity, early diagnosis, risk of developing hepatocellular carcinoma, risk indicator (alpha-fetoprotein), severe adverse events, safety (long-term), survival (long-term), intention-to-treat analysis, EORTC QLQ-C30, EORTC QLQ-LC13, EQ-5D-5L, SF-36, visual analogue scale",
      "ChunksUsed": 12,
      "ContextTokens": 3023
    },
    "NL": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "NL",
      "Outcomes": "overall survival, progression-free survivorship, response rate, adverse events, adverse events (Grade â‰¥ 3), quality of life, overall quality of life (measured with a validated and reliable instrument), local tumour control, success rate (downstaging/bridging), complications, distress, physical complaints, psychosocial complaints, emotional complaints, social complaints, spiritual complaints",
      "ChunksUsed": 12,
      "ContextTokens": 2916
    },
    "PO": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "PO",
      "Outcomes": "response rates (RECIST criteria), response rates (mRECIST), response rates (RECIS systems), response rates (multiphase computed tomography with contrast), response rates (magnetic resonance imaging with contrast), perioperative mortality, adverse events, undesirable effects, progression, time to progression, effectiveness of ablation (multiphase computed tomography with contrast), effectiveness of ablation (magnetic resonance imaging), effectiveness of ablation (ultrasonography not appropriate), completeness of ablation procedure (multiphase computed tomography with contrast), reassessment in progression classification, bridging therapy (reduction of progression), benefit from molecular chemoembolization, benefit from radioembolization, benefit from combination of loco-regional methods (chemoembolization plus thermoablation), benefit from transplantation, benefit from resection, benefit from thermoablation, benefit from radiofrequency ablation, benefit from microwave thermoablation",
      "ChunksUsed": 12,
      "ContextTokens": 2703
    },
    "SE": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "SE",
      "Outcomes": "EORTC QLQ-30, FACT-G, EORTC QLQ-HCC18, FACT-Hep, survival, quality of life",
      "ChunksUsed": 12,
      "ContextTokens": 2045
    }
  }
}